| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.06.24 | Pasinex Resources Limited: Pasinex Announces Filing of 2023 Annual Financial Results | 138 | GlobeNewswire (Europe) | TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Pasinex Resources Limited (CSE: PSE) (FSE: PNX) (The "Company" or "Pasinex") announces that, further to its news releases dated April 22, 2024, May 13, 2024... ► Artikel lesen | |
| 01.06.24 | Affimed N.V.: Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort | 334 | GlobeNewswire (Europe) | In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing... ► Artikel lesen | |
| 01.06.24 | Prospera Energy Inc. Announces 2023 Financial Results | 171 | GlobeNewswire (Europe) | CALGARY, Alberta, June 01, 2024 (GLOBE NEWSWIRE) -- Prospera Energy Inc. ("Prospera" or the "Corporation") (PEI: TSX-V; OF6A: FRA) 2023 was a transformational year for Prospera transforming to horizontal... ► Artikel lesen | |
| 01.06.24 | Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 178 | GlobeNewswire (Europe) | Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial... ► Artikel lesen | |
| 01.06.24 | Corbus Pharmaceuticals Holdings, Inc.: SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presente | 139 | GlobeNewswire (Europe) | An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR... ► Artikel lesen | |
| 01.06.24 | Y-mAbs Therapeutics, Inc.: Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting | 148 | GlobeNewswire (Europe) | NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| 01.06.24 | Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 | 193 | GlobeNewswire (Europe) | Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly... ► Artikel lesen | |
| 01.06.24 | Purple Biotech Ltd.: Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer | 207 | GlobeNewswire (Europe) | 26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC)... ► Artikel lesen | |
| 01.06.24 | Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting | 159 | GlobeNewswire (Europe) | KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and... ► Artikel lesen | |
| 01.06.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib | 154 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced... ► Artikel lesen | |
| 01.06.24 | Karyopharm Therapeutics Inc.: Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates | 201 | PR Newswire | Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficient... ► Artikel lesen | |
| 01.06.24 | CStone Pharmaceuticals: CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC | 141 | PR Newswire | EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalimab... ► Artikel lesen | |
| 01.06.24 | Hyundai Motor America Reports May 2024 Sales | 133 | PR Newswire | Total sales up 12% in May; YTD total sales increase 2%
Best May for IONIQ 5, IONIQ 6, Tucson HEV, Santa Fe HEV, Palisade and Santa Cruz
Hyundai May retail sales up 9% YOY; Volume led by Palisade... ► Artikel lesen | |
| 01.06.24 | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 | 138 | PR Newswire | Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+... ► Artikel lesen | |
| 01.06.24 | TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting | 46 | PR Newswire | Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors
A 40% overall response rate... ► Artikel lesen | |
| 01.06.24 | Eli Lilly and Company: Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO Annual Meeting | 172 | PR Newswire | Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with... ► Artikel lesen | |
| 01.06.24 | Akeso, Inc.: Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy | 150 | PR Newswire | Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46
For Subset of Patients Previously Receiving... ► Artikel lesen | |
| 01.06.24 | Deutliche Verschlechterung volkswirtschaftlicher Kennzahlen | 575 | Claus Vogt | * US-Einkaufsmanager Indizes auf Rezessionskurs * Hausse bei Gold, Silber und Minenaktien * Gold und Minenaktien haussieren auch in Aktienbaissen Liebe Leser,dass die Börse keine Einbahnstraße ist,... ► Artikel lesen | |
| 01.06.24 | Wetterdienst erwartet weitere Regenfälle im Süden | 683 | dts Nachrichtenagentur | Offenbach - Der Deutsche Wetterdienst erwartet weitere kräftige Regenfälle im Süden.Vor allem ab Sonntagmittag bis in die Nacht zum Montag kann sich der bereits laufende Dauerregen in weiten Teilen... ► Artikel lesen | |
| 01.06.24 | Aus der Traum: BVB erlebt Final-Debakel in Wembley | 1.110 | Der Aktionär | In London hat der BVB am Samstagabend das Finale der Champions League gegen Real Madrid mit 0:2 verloren. Die Schwarzgelben verpassten damit ihre erste Chance auf den Titelgewinn seit dem Final-Debakel... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 3.907 |
| TESLA | 3.093 |
| STEYR MOTORS | 2.787 |
| DEUTZ | 2.700 |
| RENK GROUP | 2.673 |
| THYSSENKRUPP | 2.608 |
| TUI | 2.277 |
| NEL | 2.174 |
| BYD | 2.126 |
| RHEINMETALL | 2.111 |
| BAYER | 1.516 |
| XIAOMI | 1.456 |
| NOVO NORDISK | 1.370 |
| EVOTEC | 1.301 |
| COMMERZBANK | 1.167 |
| DEUTSCHE BANK | 1.149 |
| BASF | 1.028 |
| VOLKSWAGEN | 996 |
| MERCEDES-BENZ | 972 |
| AIXTRON SE | 969 |
| MUTARES | 958 |
| PUMA | 937 |
| PORSCHE AG | 913 |
| SUPER MICRO COMPUTER | 847 |
| HENSOLDT | 835 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
